Results 11 to 20 of about 48,914 (162)

The trajectory of fatigue over time in breast cancer patients treated with chemotherapy: exploring the effect of anthracycline-based chemotherapy [PDF]

Breast
Background: Cancer-related fatigue is a common and profound side effect of cancer treatment. The specific impacts of different classes of chemotherapy remains understudied.
Anneke Kastelein, Laura Kervezee, Dieuwke R. Mink van der Molen, Daniel J. Evers, Carmen C. van der Pol, Annemiek Doeksen, N.H. Chavannes, Hans Gelderblom, Jacques Neefjes, Helena M. Verkooijen, Anne M. May   +10 more
doaj   +2 more sources

An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity

Frontiers in Pharmacology
Anthracycline drugs mainly include doxorubicin, epirubicin, pirarubicin, and aclamycin, which are widely used to treat a variety of malignant tumors, such as breast cancer, gastrointestinal tumors, lymphoma, etc.
Zun Wang
exaly   +3 more sources

Evaluation of the cardioprotective effect of l-carnitine and silymarin in cancer patients receiving anthracycline-containing chemotherapy [PDF]

Journal of Bioscience and Applied Research, 2020
Aim: Anthracycline-induced cardiotoxicity is the most common constraint of its use in the treatment of various types of cancer. This study aimed to investigate the benefits of the addition of the l-carnitine / silymarin to anthracycline chemotherapy in ...
Zeinab Zalat, Hosny Elewa, Mohamed Abdel-Latif, Mohamed Alm El-Din, Neeven Kohaf   +4 more
doaj   +1 more source

Comprehensive Analysis of Transcriptomics and Genetic Alterations Identifies Potential Mechanisms Underlying Anthracycline Therapy Resistance in Breast Cancer

Biomolecules, 2022
Anthracycline is a mainstay of treatment for breast cancer patients because of its antitumor activity. However, anthracycline resistance is a critical barrier in treating breast cancer.
Zihao Liu, Jingbo Gao, Ran Gu, Yu Shi, Hong Hu, Jianlan Liu, Jiefeng Huang, Caineng Zhong, Wenbin Zhou, Yaping Yang, Chang Gong   +10 more
doaj   +1 more source

Understanding Anthracycline Cardiotoxicity From Mitochondrial Aspect

Frontiers in Pharmacology, 2022
Anthracyclines, such as doxorubicin, represent one group of chemotherapy drugs with the most cardiotoxicity. Despite that anthracyclines are capable of treating assorted solid tumors and hematological malignancies, the side effect of inducing cardiac ...
Junqi Huang, Rundong Wu, Linyi Chen, Ziqiang Yang, Daoguang Yan, Mingchuan Li   +5 more
doaj   +1 more source

Cardiotoxicity of Anthracyclines [PDF]

Frontiers in Cardiovascular Medicine, 2020
Cardiotoxicity is a feared side effect that may limit the clinical use of anthracyclines. It may indeed affect the quality of life and survival of patients with cancer, regardless of oncological prognosis. This paper provides an overview of anthracycline-induced cardiotoxicity in terms of definition, classification, incidence, risk factors, possible ...
Daniela Cardinale, Fabiani Iacopo, Carlo Maria Cipolla   +2 more
openaire   +3 more sources

Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer

Cancer Treatment and Research Communications, 2023
Background: Neoadjuvant chemotherapy (NACT) with human epidermal growth factor receptor 2 (HER2) blockade is the preferred approach for treating early and locally advanced HER2-positive breast cancer. There is a lack of robust data comparing pathological
Anshul Gupta, Ajay Gogia, SVS Deo, DN Sharma, Sandip Mathur, Hari Krishna Raju Sagiraju   +5 more
doaj   +1 more source

Electrocardiographic and biochemical analysis of anthracycline induced cardiotoxicity in breast cancer patients from Southern Sri Lanka

BMC Cancer, 2023
Background The clinical application of anthracycline chemotherapy is hindered due to the cumulative dose-dependent cardiotoxicity followed by the oxidative stress initiated during the mechanism of action of anthracyclines.
Jayasinghe Arachchige Nirosha Sandamali, Ruwani Punyakanthi Hewawasam, Madappuli Arachchige Chaminda Sri Sampath Fernando, Kamani Ayoma Perera Wijewardana Jayatilaka   +3 more
doaj   +1 more source

Older patients with Hodgkin Lymphoma: Walking the tightrope of efficacy and toxicity

Frontiers in Oncology, 2023
Since its initial description, classical Hodgkin lymphoma (cHL) portends a greatly improved prognosis and the goal of treatment in most patients is cure with minimisation of toxicity from treatment.
Aisling Barrett, Graham P. Collins
doaj   +1 more source

Cardiac computed tomography‐derived myocardial tissue characterization after anthracycline treatment

ESC Heart Failure, 2022
Aims Understanding cardiac function after anthracycline administration is very important from the perspective of preventing the onset of heart failure.
Koichi Egashira, Daisuke Sueta, Masafumi Kidoh, Mai Tomiguchi, Seitaro Oda, Hiroki Usuku, Kaori Hidaka, Lisa Goto‐Yamaguchi, Aiko Sueta, Takashi Komorita, Fumi Oike, Koichiro Fujisue, Eiichiro Yamamoto, Shinsuke Hanatani, Seiji Takashio, Satoshi Araki, Kenichi Matsushita, Yutaka Yamamoto, Toshinori Hirai, Kenichi Tsujita   +19 more
doaj   +1 more source